US FDA Approves At-Home Use of Drug for Schizophrenia, Bipolar-Related Agitation
Teva Expands Igalmi Access Following New FDA Approval
According to the announcement, the approval covers the use of BioXcel Therapeutics’ drug in outpatient settings without direct supervision by a healthcare provider. Teva Pharmaceuticals, which recently acquired nearly all of BioXcel’s assets, including Igalmi, said the decision addresses a treatment gap as no FDA-approved options were previously available for this purpose in unsupervised outpatient settings.
Teva said it would announce its plans for commercialising the drug’s at-home use at a later date.
Igalmi, whose active ingredient is dexmedetomidine, was initially approved by the FDA in April 2022 as an orally dissolving sublingual film for the acute treatment of agitation associated with schizophrenia and bipolar disorder in adults. Its original approval required administration under the supervision of a healthcare professional.
Schizophrenia is a mental health condition that can involve delusions, hallucinations and disorganised thinking, while bipolar disorder is characterised by significant changes in mood, energy and activity levels.
According to Teva, agitation affects approximately 25 to 40 per cent of patients with these conditions, highlighting the need for additional treatment options.
BioXcel has also been investigating BXCL501, its proprietary dexmedetomidine film formulation, for the acute treatment of agitation associated with Alzheimer’s disease and for at-home treatment of agitation linked to schizophrenia and bipolar I or II disorder. However, the safety and effectiveness of these investigational uses have not been established.
The company has received FDA Breakthrough Therapy designation for the treatment of agitation associated with dementia and Fast Track designation for potential treatments targeting agitation linked to schizophrenia, bipolar disorders and dementia.
Comments are closed, but trackbacks and pingbacks are open.